Web Exclusives

The phase 3 S2302 Pragmatica-Lung study offers a new blueprint for cancer clinical trials, one that emphasizes simplification, inclusivity, and real-world applicability, according to Konstantin Dragnev, MD, of Dartmouth Cancer Center.

Paula Aristizabal, MD, MAS, a pediatric hematologist/oncologist at Rady Children’s Hospital-San Diego/associate professor at the University of California San Diego, and her research team developed a peer navigation intervention known as the Childhood Malignancy Peer Research Navigation (Comprendo) program. This program pairs trained parent navigators—individuals who have experienced similar challenges with their own children’s cancer care—with parents who are newer to the experience, with the intention to guide these families through the informed consent process for childhood cancer clinical trials.

n the US cohort, Black patients with HR-positive/HER2-negative mBC who underwent NGS testing were more likely to receive first-line chemotherapy, less likely to have PIK3CA mutations, and less likely to receive first-line CDK4/6 inhibitors compared with White patients.

round Zero were 3 times more likely to have genetic changes associated with an increased risk of blood cancer compared with other first responders.

The researchers noted variations in time to treatment initiation and choice of therapy across the 3 healthcare settings, with factors such as distance from the hospital and income levels playing significant roles in delays of treatment.

Following the conclusion of the OCM, which previously compensated nurses providing navigation services, practices nationwide faced revenue loss and had to adapt nurse assignments accordingly. Despite these financial setbacks, the demand for navigation services remains high due to their pivotal role in patient care and support.

The specificity of ICD-10-CM codes allows providers to communicate correct clinical information to third-party payers and across the healthcare continuum.

Artificial intelligence holds promise for detecting lung cancer if research presented at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer is any indicator.

Patients diagnosed with stage IV lung cancer displayed higher proportions of EGFR mutations compared to those without.